DOCSLIB.ORG

Peri-Operative Management of Percutaneous Fetoscopic Spina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Peri-Operative Management of Percutaneous Fetoscopic Spina International Journal of Obstetric Anesthesia (2020) 43, 97–105 0959-289X/$ - see front matter Ó 2020 Elsevier Ltd. All rights reserved. https://doi.org/10.1016/j.ijoa.2020.04.005 REVIEW ARTICLE www.obstetanesthesia.com Peri-operative management of percutaneous fetoscopic spina-bifida repair: a descriptive review of five cases from the United Kingdom, with focus on anaesthetic implications C.D. Goonasekera,a V.A. Skelton,a B. Zebian,b K. Nicolaides,c D. Araujo Lapa,d M. Santorum-Perez,e C. Bleil,b A. Hickey,f R. Bhat,f B.E. Oliva Gattog aDepartment of Anaesthesia, King’s College Hospital, London, UK bDepartment of Neurosurgery, King’s College Hospital, London, UK cFetal Medicine Research Institute, King’s College Hospital, London, UK dDepartment of Obstetrics and Fetal Medicine, Hospital Israelita Albert Einstein, Sao Paulo, Brazil eDepartment of Obstetrics and Fetal Medicine, Fetal Medicine Research Institute, King’s College Hospital, London, UK fDepartment of Neonatology, King’s College Hospital, London, UK gDepartment of Anaesthesia, Hospital Israelita Albert Einstein, Sao Paulo, Brazil ABSTRACT We present a case-based review of the first five percutaneous fetoscopic in-utero spina bifida repair procedures undertaken in the UK. Our focus is on implications of anaesthesia and analgesia for the mother and fetus, provision of uterine relaxation and fetal immobilisation while providing conditions conducive to surgical access. Minimising risks for fetal acidosis, placental and fetal hypoperfusion, maternal and fetal sepsis and maternal fluid overload were the foremost priorities. We discuss optimisation strate- gies undertaken to ensure fetal and maternal well-being under anaesthesia, shortcomings in the current approach, and possible directions for improvement. Ó 2020 Elsevier Ltd. All rights reserved. Keywords: Percutaneous fetoscopic spina-bifida repair; Transplacental anaesthesia; Fetal monitoring; Depth of anaesthesia; Uterine tocolysis Introduction with increased rates of preterm birth (13% before 30 weeks’ gestation) and uterine dehiscence. Spina bifida results from abnormal development and In the quest to reduce maternal and fetal complica- incomplete closure of the neural tube and affects 33– tions, fetoscopic approaches have been adopted by 48 per 100 000 live births globally.1 Current practice is many centres around the world with promising surgical repair within 1–2 days of birth. Recently, sev- results.6–8 There is no published guidance on optimal eral animal and human reports have suggested that pre- modes of anaesthesia. We report our first experiences natal repair could offer better postnatal neurological of percutaneous fetoscopic spina bifida repair, including function.2,3 In 2011, the Management of optimisation strategies undertaken to ensure fetal and Myelomeningocele Study (MOMS) compared open maternal well-being under anaesthesia, shortcomings (hysterotomy) prenatal repair with the standard postna- of the current approach and directions for improvement tal technique. They found reduced rates of neurosurgical in the future. intervention for hydrocephalus in a significant propor- tion of those treated prenatally and an improved com- Case series posite score for mental development and motor function at 30 months.4,5 However, it was associated Eligibility The MOMS trial criteria were used to determine eligibil- Accepted April 2020 ity for antenatal repair. All cases had fetal spina bifida Correspondence to: C. Goonasekera, Department of Anaesthetics, recognised on antenatal ultrasound and confirmed by King’s College Hospital, Denmark Hill, London SE5 9RS, UK. E-mail address: [email protected] magnetic resonance imaging (MRI) early in the second 98 Peri-operative management of percutaneous fetoscopic spina-bifida repair trimester. None of the fetuses had any other congenital tained at 2–3 mmHg above the opening pressure. We abnormalities. The parents were counselled on the observed momentary drops in blood pressure during options available for repair and, following a multidisci- the insertion of trocars. Uterine insufflation with CO2 plinary discussion, the percutaneous fetoscopic seemed most stimulating for the mother, with a rise in approach was offered. The parents gave consent and blood pressure and BIS that was mitigated by IV mor- surgery was scheduled for the late second trimester. phine. The spinal defect was dissected by the neuro- surgeon and repaired with a bio-cellulose patch placed Operative course over the neural placode (exposed open spinal cord), cov- ered by an additional layer of a skin substitute (Neve- Extensive pre-operative planning was undertaken with Ò advice from international experts. All team members lia , Symatese, Montpelier, France) as needed (Fig. 1). participated in a simulation on the day of surgery. The uterine cavity was irrigated with warm (37 °C) Before surgery, the women were fasted, provided with Ringer’s lactate solution, antibiotic instilled (cefuroxime standard antacid premedication and anti-thrombo- 1.5 g in case 1, clindamycin 500 mg in cases 2–5) and the embolic stockings, and given rectal (PR) indomethacin cavity re-filled with 1L Ringer’s lactate solution or the 11 100 mg 12 h pre-operatively. Following pre- drained amniotic fluid if not blood-stained. Uterine oxygenation, a rapid sequence induction was carried tone was restored with termination of the GTN infusion out with intravenous (IV) fentanyl 3 mg/kg, propofol and sevoflurane inhalation 5 min before removal of the 1.5 mg/kg and rocuronium 0.8 mg/kg. This generally trocars. Intravenous anaesthesia was maintained during achieved a bispectral index (BIS) of 25–30. Following uterine port-site haemostasis and closure of abdominal intubation, positive-pressure ventilation was established wounds. The duration of the procedure ranged from with hyperventilation during intra-uterine carbon diox- 4.0 to 5.5 h. Maternal temperature was monitored and ide (CO2) insufflation to maintain end-tidal CO2 maintained with a warm-air blanket. Women received (ETCO2) below 3.5 kPa. Antibiotic prophylaxis was IV paracetamol 1 g, IV metoclopramide 10 mg and PR administered at induction (cefuroxime 1.5 g in case 1 indomethacin 100 mg. The maternal blood loss was and clindamycin 600 mg in cases 2–5), with three further approximately 150–200 mL and total fluids during the doses postoperatively. procedure limited to Hartmann’s solution 1000– Anaesthesia was maintained with sevoflurane at a 1500 mL. Following recovery from general anaesthesia, minimum alveolar concentration (MAC) of 0.4–1, intra- the mothers and fetuses were observed in the obstetric venous propofol infusion 2–3 mg/kg/h and remifentanil high dependency unit for 24–48 h. Adequate pain con- infusion 10 mg/kg/h adjusted to maintain cardiovascular trol was achieved with regular paracetamol and doses stability. The depth of maternal anaesthesia was moni- of oral morphine (0.15 mg/kg) except in case 2, for tored using BIS and maintained at 40.9 An arterial line whom morphine patient controlled analgesia followed was inserted to assist regular sampling and cardiovascu- by epidural analgesia was required from days 2–4 lar monitoring. because of intermittent shooting postoperative pain trig- A phenylephrine infusion was titrated to maintain a gered by fetal movements impinging upon the uterine target mean maternal blood pressure (65–70 mmHg in wounds. None of the women required a blood trans- cases 1 and 2 and 80 mmHg in cases 3–5) during the pro- fusion. There were no post-procedure placental abrup- cedure. Atropine 600 mg (cases 3–5) was given if the tions or uterine dehiscences. maternal heart rate fell below 60/min. A glyceryl trini- trate (GTN) infusion was available (50 mg/50 mL) to Fetal monitoring provide additional uterine relaxation. This was required Intra-operative fetal monitoring was obstetrician led. in case 4 during which intermittent uterine contractions For case 1 this included pre- and postoperative ultra- were observed following an intraperitoneal CO2 leak sound assessment of umbilical and middle cerebral during the procedure. artery blood flow and cardiotocogram (CTG), with All women were placed in a semi-lithotomy/supine visual monitoring of the umbilical cord pulsation position, a urinary catheter inserted and PR indometha- intra-operatively. The uterine and middle cerebral artery cin 100 mg given for uterine tocolysis. An 18-gauge nee- blood flows were reported as normal before and after dle was inserted into the uterus under ultrasound surgery. The beat-to-beat variation of the fetal heart guidance and 500 mL of warm Ringer’s lactate solution on CTG was reduced postoperatively in case 1, although infused. Four percutaneous ports (in case 1) and three the baseline rate remained normal. Normal fetal move- ports (in cases 2–5) were respectively inserted into the ments were felt by the mother 48 h post-surgery. uterus under ultrasound guidance. Approximately 1 L In cases 2–5, additional intra-operative fetal monitor- of amniotic fluid was removed and humidified warm ing was instituted every 15 min using a Doppler probe CO2 insufflated. The uterine ‘opening pressure’ was placed on the maternal flank under sterile conditions measured and the maximum insufflation pressure set to gain umbilical artery signals from the umbilical cord, 10 at 4 mmHg above it. In cases 2–5, pressure was main- below the amniotic fluid level so as to avoid the CO2 C.D. Goonasekera et al. 99 Fig. 1 Completed fetoscopic patch repair of the spina-bifida (case 1) interface (Fig. 2). This fetal umbilical cord blood flow ventriculomegaly (Fig. 3). On neurological examination, study was used to calculate the pulsatility index (PI), the baby displayed good power and movement in all the systolic velocity-diastolic velocity/mean velocity, limbs and normal anal tone, and the bladder scan was which is a measure of umbilical cord forward blood within the normal range. At 48 h, there was renal flow, and placental resistance.12 The PI reduced with impairment with the s. creatinine rising to a maximum increasing gestation. A PI <1.0 was considered healthy of 289 mmol/L.
Load more

Recommended publications
  • Refusal to Undergo a Cesarean Section: a Woman's Right Or a Criminal Act ? Monica K
    Health Matrix: The Journal of Law- Medicine Volume 15 | Issue 2 2005 Refusal to Undergo a Cesarean Section: A Woman's Right or a Criminal Act ? Monica K. Miller Follow this and additional works at: https://scholarlycommons.law.case.edu/healthmatrix Part of the Health Law and Policy Commons Recommended Citation Monica K. Miller, Refusal to Undergo a Cesarean Section: A Woman's Right or a Criminal Act ?, 15 Health Matrix 383 (2005) Available at: https://scholarlycommons.law.case.edu/healthmatrix/vol15/iss2/6 This Article is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Health Matrix: The ourJ nal of Law-Medicine by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons. REFUSAL TO UNDERGO A CESAREAN SECTION: A WOMAN'S RIGHT OR A CRIMINAL ACT? Monica K. Millert INTRODUCTION In March, 2004, Melissa Ann Rowland, a twenty-eight-year-old woman from Salt Lake City, gained national media attention when she was arrested on charges of homicide relating to the death of her son. Although there are many child homicide cases that occur regularly across the country that do not attract wide-spread media attention, this case was exceptional because her son died before he was ever born. 1 Rowland had sought medical treatment several times between late December 2003 and January 9, 2004. Each time, she was allegedly advised to get immediate medical treatment, including a cesarean sec- tion (c-section), because her twin fetuses were in danger of death or serious injury.
    [Show full text]
  • Caesarean Section Or Vaginal Delivery in the 21St Century
    CAESAREAN SECTION OR VAGINAL DELIVERY IN THE 21ST CENTURY ntil the 20th Century, caesarean fluid embolism. The absolute risk of trans-placentally to the foetus, prepar- section (C/S) was a feared op- death with C/S in high and middle- ing the foetus to adopt its mother’s Ueration. The ubiquitous classical resource settings is between 1/2000 and microbiome. C/S interferes with neonatal uterine incision meant high maternal 1/4000 (2, 3). In subsequent pregnancies, exposure to maternal vaginal and skin mortality from bleeding and future the risk of placenta previa, placenta flora, leading to colonization with other uterine rupture. Even with aseptic surgi- accreta and uterine rupture is increased. environmental microbes and an altered cal technique, sepsis was common and These conditions increase maternal microbiome. Routine antibiotic exposure lethal without antibiotics. The operation mortality and severe maternal morbid- with C/S likely alters this further. was used almost solely to save the life of ity cumulatively with each subsequent Microbial exposure and the stress of a mother in whom vaginal delivery was C/S. This is of particular importance to labour also lead to marked activation extremely dangerous, such as one with women having large families. of immune system markers in the cord placenta previa. Foetal death and the use blood of neonates born vaginally or by of intrauterine foetal destructive proce- Maternal Benefits C/S after labour. These changes are absent dures, which carry their own morbidity, C/S has a modest protective effect against in the cord blood of neonates born by were often preferable to C/S.
    [Show full text]
  • Clinical Policy: Fetal Surgery in Utero for Prenatally Diagnosed
    Clinical Policy: Fetal Surgery in Utero for Prenatally Diagnosed Malformations Reference Number: CP.MP.129 Effective Date: 01/18 Coding Implications Last Review Date: 09/18 Revision Log Description This policy describes the medical necessity requirements for performing fetal surgery. This becomes an option when it is predicted that the fetus will not live long enough to survive delivery or after birth. Therefore, surgical intervention during pregnancy on the fetus is meant to correct problems that would be too advanced to correct after birth. Policy/Criteria I. It is the policy of Pennsylvania Health and Wellness® (PHW) that in-utero fetal surgery (IUFS) is medically necessary for any of the following: A. Sacrococcygeal teratoma (SCT) associated with fetal hydrops related to high output heart failure : SCT resecton: B. Lower urinary tract obstruction without multiple fetal abnormalities or chromosomal abnormalities: urinary decompression via vesico-amniotic shunting C. Ccongenital pulmonary airway malformation (CPAM) and extralobar bronchopulmonary sequestration with hydrops (hydrops fetalis): resection of malformed pulmonary tissue, or placement of a thoraco-amniotic shunt; D. Twin-twin transfusion syndrome (TTTS): treatment approach is dependent on Quintero stage, maternal signs and symptoms, gestational age and the availability of requisite technical expertise and include either: 1. Amnioreduction; or 2. Fetoscopic laser ablation, with or without amnioreduction when member is between 16 and 26 weeks gestation; E. Twin-reversed-arterial-perfusion (TRAP): ablation of anastomotic vessels of the acardiac twin (laser, radiofrequency ablation); F. Myelomeningocele repair when all of the following criteria are met: 1. Singleton pregnancy; 2. Upper boundary of myelomeningocele located between T1 and S1; 3.
    [Show full text]
  • Fetal Surgery in Utero for Prenatally Diagnosed Malformations
    Clinical Policy: Fetal Surgery in Utero for Prenatally Diagnosed Malformations Reference Number: PA.CP.MP.129 Effective Date: 01/18 Coding Implications Last Review Date: 12/18 Revision Log Description This policy describes the medical necessity requirements for performing fetal surgery. This becomes an option when it is predicted that the fetus will not live long enough to survive delivery or after birth. Therefore, surgical intervention during pregnancy on the fetus is meant to correct problems that would be too advanced to correct after birth. Policy/Criteria I. It is the policy of Pennsylvania Health and Wellness® (PHW) that in-utero fetal surgery (IUFS) is medically necessary for any of the following: A. Sacrococcygeal teratoma (SCT) associated with fetal hydrops related to high output heart failure : SCT resection; B. Lower urinary tract obstruction without multiple fetal abnormalities or chromosomal abnormalities: urinary decompression via vesico-amniotic shunting C. Congenital pulmonary airway malformation (CPAM) and extralobar bronchopulmonary sequestration with hydrops (hydrops fetalis): resection of malformed pulmonary tissue, or placement of a thoraco-amniotic shunt; D. Twin-twin transfusion syndrome (TTTS): treatment approach is dependent on Quintero stage, maternal signs and symptoms, gestational age and the availability of requisite technical expertise and include either: 1. Amnioreduction; or 2. Fetoscopic laser ablation, with or without amnioreduction when member is between 16 and 26 weeks gestation; E. Twin-reversed-arterial-perfusion (TRAP): ablation of anastomotic vessels of the acardiac twin (laser, radiofrequency ablation); F. Myelomeningocele repair when all of the following criteria are met: 1. Singleton pregnancy; 2. Upper boundary of myelomeningocele located between T1 and S1; 3.
    [Show full text]
  • Guide to Learning in Maternal-Fetal Medicine
    GUIDE TO LEARNING IN MATERNAL-FETAL MEDICINE First in Women’s Health The Division of Maternal-Fetal Medicine of The American Board of Obstetrics and Gynecology, Inc. 2915 Vine Street Dallas, TX 75204 Direct questions to: ABOG Fellowship Department 214.871.1619 (Main Line) 214.721.7526 (Fellowship Line) 214.871.1943 (Fax) [email protected] www.abog.org Revised 4/2018 1 TABLE OF CONTENTS I. INTRODUCTION ........................................................................................................................ 3 II. DEFINITION OF A MATERNAL-FETAL MEDICINE SUBSPECIALIST .................................... 3 III. OBJECTIVES ............................................................................................................................ 3 IV. GENERAL CONSIDERATIONS ................................................................................................ 3 V. ENDOCRINOLOGY OF PREGNANCY ..................................................................................... 4 VI. PHYSIOLOGY ........................................................................................................................... 6 VII. BIOCHEMISTRY ........................................................................................................................ 9 VIII. PHARMACOLOGY .................................................................................................................... 9 IX. PATHOLOGY .........................................................................................................................
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Leapfrog Hospital Survey Hard Copy
    Leapfrog Hospital Survey Hard Copy QUESTIONS & REPORTING PERIODS ENDNOTES MEASURE SPECIFICATIONS FAQS Table of Contents Welcome to the 2016 Leapfrog Hospital Survey........................................................................................... 6 Important Notes about the 2016 Survey ............................................................................................ 6 Overview of the 2016 Leapfrog Hospital Survey ................................................................................ 7 Pre-Submission Checklist .................................................................................................................. 9 Instructions for Submitting a Leapfrog Hospital Survey ................................................................... 10 Helpful Tips for Verifying Submission ......................................................................................... 11 Tips for updating or correcting a previously submitted Leapfrog Hospital Survey ...................... 11 Deadlines ......................................................................................................................................... 13 Deadlines for the 2016 Leapfrog Hospital Survey ...................................................................... 13 Deadlines Related to the Hospital Safety Score ......................................................................... 13 Technical Assistance.......................................................................................................................
    [Show full text]
  • Update on Prenatal Diagnosis and Fetal Surgery for Myelomeningocele
    Review Arch Argent Pediatr 2021;119(3):e215-e228 / e215 Update on prenatal diagnosis and fetal surgery for myelomeningocele César Meller, M.D.a, Delfina Covini, M.D.b, Horacio Aiello, M.D.a, Gustavo Izbizky, M.D.a, Santiago Portillo Medina, M.D.c and Lucas Otaño, M.D.a ABSTRACT This powered research in two A seminal study titled Management of critical areas. On the one side, prenatal Myelomeningocele Study, from 2011, demonstrated that prenatal myelomeningocele defect repaired myelomeningocele diagnosis within before 26 weeks of gestation improved the therapeutic window became a neurological outcomes; based on this study, fetal mandatory goal; therefore, research surgery was introduced as a standard of care efforts on screening strategies were alternative. Thus, prenatal myelomeningocele diagnosis within the therapeutic window became intensified, especially in the first a mandatory goal; therefore, research efforts on trimester. On the other side, different screening strategies were intensified, especially fetal surgery techniques were assessed in the first trimester. In addition, different fetal to improve neurological outcomes and surgery techniques were developed to improve neurological outcomes and reduce maternal reduce maternal risks. The objective risks. The objective of this review is to provide an of this review is to provide an update update on the advances in prenatal screening and on the advances in prenatal screening diagnosis during the first and second trimesters, and diagnosis and in fetal surgery for and in open and fetoscopic fetal surgery for myelomeningocele. myelomeningocele. Key words: myelomeningocele, fetal therapies, spina bifida, fetoscopy, antenatal care. EPIDEMIOLOGY The prevalence of spina bifida http://dx.doi.org/10.5546/aap.2021.eng.e215 varies markedly worldwide based on ethnic and geographic To cite: Meller C, Covini D, Aiello H, Izbizky G, characteristics.8,9 In Argentina, since et al.
    [Show full text]
  • Clinical Practice Guideline: Planning for Labor and Vaginal Birth After Cesarean
    Clinical Practice Guideline: Planning for Labor and Vaginal Birth After Cesarean These recommendations are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient’s family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. American Academy of Family Physicians AAFP Board Approved May 2014 American Academy of Family Physicians | Clinical Practice Guideline: Planning for Labor and Vaginal Birth After Cesarean | page 1 ABSTRACT. Purpose. Cesarean deliveries are a common surgical procedure in the United States, accounting for one in three U.S. births. The primary purpose of this guideline is to provide clinicians with evidence to guide planning for labor and vaginal birth after cesarean (LAC/VBAC). Methods. A multidisciplinary guideline development group (GDG) representing family medicine, epidemiology, obstetrics, midwifery, and consumer advocacy used a recent high quality systematic review by the Agency for Healthcare Research and Quality (AHRQ) as the primary evidence source and updated the AHRQ systematic review to include research published through September 2012. The GDG conducted a systematic review for an additional key question on facilities and resources needed for LAC/VBAC. The GDG developed recommendations using a modified Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Results. The panel recommended that an individualized assessment of risks and benefits be discussed with pregnant women with a history of one or more prior cesarean births who are deciding between a planned LAC/VBAC and a repeat cesarean birth.
    [Show full text]
  • (EXIT), a Resuscitation Option for Intra-Thoracic Foetal Pathologies
    Original article SWISS MED WKLY 2007;137:279–285 · www.smw.ch 279 Peer reviewed article Ex utero intrapartum treatment (EXIT), a resuscitation option for intra-thoracic foetal pathologies Christian Kerna, Michel Ange, Moralesb, Barbara Peiryc, Riccardo E. Pfisterc a Anaesthesia, University Hospital Geneva, Switzerland b Gynaecology and Obstetrics, University Hospital Geneva, Switzerland c Paediatrics, University Hospital Geneva, Switzerland Summary The ex utero intrapartum treatment (EXIT) requires a caesarean section that specifically differs procedure is designed to guarantee sufficient oxy- from the traditional caesarean section during genation for a foetus at risk of airway obstruction. which uterine tone is maintained to minimize ma- This is achieved by improving lung ventilation, ternal bleeding. To guarantee foetal oxygenation usually by establishing an airway during caesarean during the EXIT procedure, profound uterine delivery whilst preserving the foetal-placental cir- relaxation is desired. To gain time with optimal culation temporarily. Indications for the EXIT placental oxygenation in order to safely perform an procedure have extended from its original use in airway intervention in a baby at risk of hypoxia may reversing iatrogenic tracheal obstruction in con- require deep inhalation anaesthesia and/or to- genital diaphragmatic hernia to naturally occur- colytic agents. We review the EXIT procedure and ring upper airway obstructions. We report our present a case series from the University Hospital experience with a new and rarely mentioned indi- of Geneva that contrasts with the common indica- cation for the EXIT procedure, intra-thoracic tion for the EXIT procedure usually based on volume expansions. The elaboration of lowest risk upper airway obstruction by its exclusive indica- scenarios through balancing risks with alternative tion for intra-thoracic malformations/diseases.
    [Show full text]
  • CP.MP.129 Fetal Surgery in Utero
    Clinical Policy: Fetal Surgery in Utero for Prenatally Diagnosed Malformations Reference Number: CP.MP.129 Coding Implications Date of Last Revision: 07/21 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description This policy describes the medical necessity requirements for performing fetal surgery. This becomes an option when it is predicted that the fetus will not live long enough to survive delivery or after birth. Therefore, surgical intervention during pregnancy on the fetus is meant to correct problems that would be too advanced to correct after birth. Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that in-utero fetal surgery (IUFS) is medically necessary for any of the following: A. Sacrococcygeal teratoma (SCT): SCT resection or a minimally invasive approach; B. Lower urinary tract obstruction without multiple fetal anomalies or chromosomal abnormalities: urinary decompression via vesico-amniotic shunting; C. Congenital pulmonary airway malformation (CPAM) and extralobar bronchopulmonary sequestration (BPS), with high risk tumors: resection of malformed pulmonary tissue, or placement of a thoraco-amniotic shunt; D. Placement of a thoraco-amniotic shunt for pleural effusion with or without secondary fetal hydrops; E. Twin-twin transfusion syndrome (TTTS): treatment approach is dependent on Quintero stage, maternal signs and symptoms, gestational age and the availability of requisite technical expertise and include either: 1. Amnioreduction; or 2. Fetoscopic laser ablation, with or without amnioreduction when pregnancy is between 16 and 26 weeks gestation; F. Twin-reversed-arterial-perfusion sequence (TRAP): ablation of anastomotic vessels of the acardiac twin (laser, radiofrequency ablation); G.
    [Show full text]
  • Global Maternity & Multiple Births Billing Guidelines
    Global Maternity & Multiple Births Billing Guidelines Quick Reference Guide Global Maternity Global maternity care includes pregnancy-related antepartum care, admission to labor and delivery, management of labor including fetal monitoring, delivery, and uncomplicated postpartum care until six weeks postpartum. A global charge should be billed for maternity claims when all maternity-related services, as outlined in Blue Cross and Blue Shield of North Carolina’s (BCBSNC’s) corporate medical policy “Guidelines for Global Maternity Reimbursement,” are provided by the same physician or physicians practicing at the same location. The number of antepartum visits may vary from patient to patient. If global maternity care is provided, all maternity related visits and delivery should be billed under the global maternity code. Individual E&M codes should not be billed to report maternity-related E&M visits. Prenatal care is considered an integral part of the global reimbursement and will not be paid separately The Current Procedural Terminology® (CPT) manual identifies the following CPT codes as global maternity services: 59400 - Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartu m care 59510 - Routine obstetric care including antepartum care, cesarean delivery and postpartum care 59610 - Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartu m care, after previous cesarean delivery 59618 - Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal deliver y after previous cesarean delivery Billing tips: An initial visit, confirming the pregnancy, is not a part of global maternity care services (verification of benefits will determine appropriate member liability).
    [Show full text]